AS OF: IULY 31, 2018

# **ACATIS**

# Global balanced fund, flexible

# **MARKET COMMENTARY**

The fund price improved by 1.7% in July. It has gained 4.3% since the start of the year. In the reporting month, Grenke announced a 23% increase in profits  $\,$ for the first six months of 2018. With this announcement, the leasing specialist confirmed its dynamic growth rate, although it initially maintained the annual forecast for the increase in profits with a range of 16% to 22%. We expect that the budget figures will be increased after the end of the third quarter, LMVH and Microsoft impressed with 28% and 10% higher results for the current year. On the other hand, brewery group AB InBev missed market expectations despite a 7% increase in the operating result; however, the company held out the prospect of improved developments in the second half of the year. Berkshire Hathaway removed the buy-back threshold for the existing share buy-back programme. It had restricted the purchase of own shares to a face value of 120% of the book value

### **INVESTMENT OBJECTIVE AND - PHILOSOPHY**

In the selection of the fund's positions the philosophy of value investing is combined with an "event-driven value" approach. The aim is to reduce fundamental risks in the selection of the fund's positions by focusing on companies with strong business quality. By business quality the management means business models that stand out for their sustainability, the ability to defend an existing competitive advantage and the capacity to generate high free cash flows. The portfolio is diversified through various types of event and different holding periods. Interest paper and bonds can be added to the portfolio.

# PRODUCT FACTS/ EMT

| WKN                 | A0X754 (Cl. A)<br>A1C5D1 (Cl. B, Inst.)<br>A1T73W (Cl. C)<br>A2DR2M (Cl. D)<br>A2H7NC (Cl. X)                        | Gi<br>Be  |  |  |  |  |
|---------------------|--|-----------|--|--|--|--|
| ISIN                | DE000A0X7541 (Cl. A)<br>DE000A1C5D13 (Cl. B)<br>DE000A1T73W9 (Cl. C)<br>DE000A2DR2M0 (Cl. D)<br>DE000A2H7NC9 (Cl. X) |           |  |  |  |  |
| Distribution        | Dividends reinvested (Cl. A, B) Divid. distrib. quarterly (Cl. C) Divid. distributed (Cl. D, X)                      |           |  |  |  |  |
| Investment category | Balanced Fund Global Flexible  | Ν         |  |  |  |  |
| Benchmark           | 50% MSCI World Perfgdr- EUR,<br>50% EONIA TR   | М         |  |  |  |  |
| Currency            | EUR  |           |  |  |  |  |
| Total net asstes    | 2,230.4 Mill. EUR  |           |  |  |  |  |
| Net asset value     | 254.45 EUR (CI.A)<br>17,389.16 EUR (CI.B)<br>1,236.97 EUR (CI.C)   | Inv<br>(m |  |  |  |  |

# 103.69 EUR (Cl. X) UI-Team, Advisor: ACATIS Manager Investment company Universal Investment Domicile Germany Hauck&Aufhäuser, FFM Custodian Dec. 15, 2008 (Cl. A) Oct. 15, 2010 (Cl. B) Jul. 10, 2013 (Cl. C) Jun. 7, 2017 (Cl. D) Dec. 22, 2017 (Cl. X) Date of inception Sep. 30 Fiscal year end **UCITS IV**

Investment horizon Investment horizon 4 of 7

CI, A, B, C, X: DE, AT, CH, ES, FR, Permission for public NL distribution CI, D: DE

Risk-return profile

Representative in Switzerland Paying agent in Switzerland

1741 Fund Solutions AG Notenstein La Roche Privatbank AG

# **TOP 10 POSITIONS**

| Grenke                   | 7.8% |
|--------------------------|------|
| Berkshire Hathaway A     | 7.6% |
| L'Occitane International | 5.4% |
| Apple                    | 5.3% |
| Linde Inhaber-Akt        | 4.6% |
| Novo Nordisk             | 4.2% |
| AB Inbev                 | 4.1% |
| Ryman Healthcare         | 3.8% |
| Nestlé                   | 3.6% |
| Münchener Rück           | 3.5% |

# PERFORMANCE VS. INDEX MSCI WORLD (50%), EONIA TR (50%)




### PERFORMANCE AS OF END OF MONTH\*

|      | Jan  | Feb  | Mar  | Apr  | May  | Jun  | Jul  | Aug  | Sep  | Oct  | Nov  | Dec  | Year | Index |
|------|------|------|------|------|------|------|------|------|------|------|------|------|------|-------|
| 2018 | 1.7  | -1.3 | -2.1 | 3.0  | 2.5  | -1.1 | 1.7  |      |      |      |      |      | 4.3  | 3.3   |
| 2017 | -0.1 | 3.0  | 0.9  | 1.2  | 0.4  | 0.5  | 0.2  | 1.0  | 0.7  | 1.7  | -0.1 | -0.6 | 8.9  | 3.8   |
| 2016 | -3.0 | 1.2  | 0.6  | -1.6 | 1.6  | -1.4 | 3.2  | 0.2  | -2.4 | 0.8  | 0.7  | 2.9  | 2.5  | 5.7   |
| 2015 | 1.9  | 2.4  | 2.1  | -0.4 | 0.9  | -1.9 | 2.5  | -2.1 | -1.3 | 2.2  | 2.2  | -1.9 | 6.5  | 5.7   |
| 2014 | -0.8 | 1.6  | 1.8  | 0.7  | 0.5  | -0.4 | 0.1  | 1.0  | 1.2  | -1.3 | 2.8  | 0.0  | 7.4  | 9.9   |
| 2013 | 3.1  | 2.6  | 1.7  | 0.0  | 1.1  | -0.9 | 0.2  | -1.4 | 0.2  | 1.1  | 0.9  | -0.4 | 8.4  | 10.6  |
| 2012 | 3.1  | 4.2  | 1.1  | -0.4 | -1.7 | 0.8  | 2.1  | 0.7  | 1.4  | 0.8  | 0.3  | 0.2  | 13.2 | 7.2   |
| 2011 | 0.6  | 1.8  | -1.1 | 0.8  | 1.5  | -0.7 | -0.8 | -5.5 | -2.1 | 5.2  | -1.3 | 3.9  | 1.9  | -0.2  |
| 2010 | 1.2  | 3.1  | 2.9  | 0.9  | -1.6 | 2.0  | 2.2  | -0.2 | 1.3  | 3.5  | -2.1 | 3.5  | 17.8 | 10.2  |
| 2009 | -0.6 | -3.5 | 2.3  | 11.2 | 5.8  | -0.5 | 4.6  | 2.2  | 4.3  | -0.9 | 1.4  | 2.1  | 31.5 | 14.6  |

|  |       | ance  | ance  |      |      | Volatility<br>3-years | I-year ' | Volatility<br>since<br>inception |  |
|--|-------|-------|-------|------|------|-----------------------|----------|----------------------------------|--|
| 158.0%   | 10.3% | 33.6% | 15.2% | 7.0% | 5.4% | 5.9%                  | 5.6%     | 7.3%                             |  |
| Volatility on monthly basis Source: Bloomberg, ACATIS Resear |       |       |       |      |      |                       |          | ATIS Research                    |  |

# **ASSET ALLOCATION - CLASSES**



# ONTINUATION PRODUCT FACTS/ EMT

| Investor type<br>(minimum requirement)       | Private Customer<br>exclusively Institutional<br>investors (Cl. X)            |
|--|---|
| Investment objective                         | Capital Accumulation  |
| Skills/ Experiences<br>(minimum requirement) | Basics  |
| Loss Carrying Capacity                       | no Capital Guarantee  |
| Front end fee                                | 5%  |
| Ongoing Charges<br>(as of Sep. 30, 2017)     | 1.79% p.a. (Cl. A, C)<br>1.40% p.a. (Cl. B)<br>0.91% p.a. (Cl. D)             |
| Management fee ex ante                       | 1.35% (Cl. A), 0.95% (Cl. B)<br>1.13% (Cl. C), 0.20% (Cl. D)<br>1.01% (Cl. X) |
| Transaction costs ex ante                    | 0.11%   |
| Performance fee ex ante                      | maximal 20%   |
| Incidental costs ex ante                     | 0.39% (Cl. A), 0.42% (Cl. B)<br>0.33% (Cl. C)                                 |

# **AWARDS**



(All general data refer to share class A)













Sauren Research **(B)** Scope Rating \*\*\*\* Morningstar top rating (3 years)

